Skip to main content
Log in

Metabolism and excretion of methylproscillaridin by man

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

0.5 mg3H-proscillaridin-4-methylether was administered orally to 5 healthy males. Maximum plasma levels of total radioactivity were reached after one to two hours. In two subjects a second peak was observed between 6 and 12 hours. The plasma half life of total radioactivity was 51 hours. 20% and 56% respectively of the dose were eliminated in urine and faeces during the following 7 days. 55% of the total radioactivity in plasma, 80% in urine and 20% in faeces consisted of CHCl3-insoluble compounds. 50 – 60% of the latter in plasma and urine could be hydrolysed by β-glucuronidase. More than 90% of the split products were identified as conjugates of methylproscillaridin. TLC-separation of the CHCl3-soluble fractions of plasma and urine yielded two unidentified metabolites, P2 and P3, as the main compounds, besides methylproscillaridin, proscillaridin and scillarenin. In faeces more than 90% of the non-polar fraction was identified as methylproscillaridin. Shortly after administration of3H-methylproscillaridin, the radioactivity in plasma consisted mainly of CHCl3-in-soluble conjugates and of the metabolite P2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Barlow, J.J., Kellie, A.E.: A quantitative method for the chromatographic separation of 17-oxo-steroid sulfates from 17-oxo-steroid glucuronides: with observation on the behaviour of conjugated corticosteroids on the same system. Biochem. J.71 86–91 (1959)

    Google Scholar 

  • Belz, G.G., Brech, W.J.: Plasmaspiegel und Kumulationsverhalten von Proscillaridin bei Niereninsuffizienz. Klin. Wschr.52 640–644 (1974)

    Google Scholar 

  • Bulger, W.H., Stohs, S.J., Wheeler, D.M.S.: 6β-Hydroxy-3 epi-digitoxigenin — the major metabolite of digitoxigenin by rabbit liver homogenates. Biochem. Pharmacol.23 921–929 (1974)

    Google Scholar 

  • Hänel, J., Meiffert, G.: Klinisch experimentelle Studie zur Charakterisierung eines Herzglykosids. Med. Welt17 1404–1408 (1966)

    Google Scholar 

  • Herrmann, I., Repke, K.: Konjugation von Cardenolidgeninen mit Schwefelsäure und Glucuronsäure. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.248 370–384 (1964)

    Google Scholar 

  • Kaiser, F.: Teilsynthetische Herzglykosid — Derivate mit verbesserter enteraler Wirksamkeit. 28. Mitteilung über Herzglykoside. Planta med. (Stuttg.)20 Suppl. 4, 52–60 (1971)

    Google Scholar 

  • Kesselring, K.: Versuche zur Pharmakokinetik und zum Stoffwechsel von Proscillaridin-4-methyläther (Ky 18). Unveröffentlichte Ergebnisse (1974)

  • Kubicek, F., Lindner, A., Polzer, K.: Zur Pharmakologie und therapeutischer Anwendung des Proscillaridin A. Wien. Klin. Wschr.77 12–16 (1965)

    Google Scholar 

  • Kuhlmann, J., Abshagen, U., Rietbrock, N.: Pharmacokinetics and metabolism of digoxigenin — mono — digitoxoside in man. Europ. J. clin. Pharmacol.7 87–94 (1974)

    Google Scholar 

  • Lauterbach, F., Repke, K.: Die fermentative Abspaltung von D-Digitoxose, D-Cymarose und L-Thevetose aus Herzglykosiden durch Leberschnitte. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.239 196–218 (1960)

    Google Scholar 

  • Lüllmann. H., Peters, T.: The cardioactivity of digitoxin metabolites. Europ. J. Pharmacol.14 204–205 (1971)

    Google Scholar 

  • Meier, G., Wagner, G.: Therapeutische Erfahrungen mit einem neuen Herzglykosid: Proscillaridin A. Med. Welt35 1995–2002 (1965)

    Google Scholar 

  • Repke, K.: Metabolism of cardiac glycosides. Proc. First Int. Pharmacol. Mtg., Stockholm 1961, Vol. 3 p 47, Oxford: Oxford University Press 1963

    Google Scholar 

  • Rietbrock, N., Vöhringer, H.-F.: Metabolism and excretion of3H-digitoxin in the rat. Biochem. Pharmacol.23 2567–2575 (1974)

    Google Scholar 

  • Staud, R., Rietbrock, N., Fassbender, H.-P.: Excretion of methylproscillaridin in patients with biliary fistula. In preparation

  • Vöhringer, H.-F., Rietbrock, N.: Metabolism and excretion of3H-digitoxin in man. Clin. Pharmacol. Ther.16 796–806 (1974)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by the Deutsche Forschungsgemeinschaft and by the Knoll AG

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rietbrock, N., Staud, R. Metabolism and excretion of methylproscillaridin by man. Eur J Clin Pharmacol 8, 427–432 (1975). https://doi.org/10.1007/BF00562317

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562317

Key words

Navigation